Sona Nanotech Inc. logo

Sona Nanotech Inc. (SONA)

Market Closed
12 Dec, 20:00
CNSX CNSX
CA$
0. 49
+0.01
+1.02%
CA$
29.25M Market Cap
- P/E Ratio
0% Div Yield
22,535 Volume
- Eps
CA$ 0.49
Previous Close
Day Range
0.48 0.5
Year Range
0.24 0.91
Want to track SONA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 74 days

Summary

SONA closed yesterday higher at CA$0.49, an increase of 1.02% from Thursday's close, completing a monthly decrease of -4.81% or CA$0.03. Over the past 12 months, SONA stock gained 98%.
SONA is not paying dividends to its shareholders.
The last earnings report, released on Sep 25, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Feb 25, 2026.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on CNSX (CAD).

SONA Chart

Similar

Hybrid Power Solutions Inc.
CA$ -
-
Cybeats Technologies Corp.
CA$ 0.13
0%
FNQ
Fineqia International Inc.
CA$ 0.01
0%
PKK
Tenet Fintech Group Inc.
CA$ 0.03
0%
Blockchain Venture Capital Inc.
CA$ 0.19
+2.7%

Sona Nanotech Inc. (SONA) FAQ

What is the stock price today?

The current price is CA$0.49.

On which exchange is it traded?

Sona Nanotech Inc. is listed on CNSX.

What is its stock symbol?

The ticker symbol is SONA.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 29.25M.

When is the next earnings date?

The next earnings report will release on Feb 25, 2026.

Has Sona Nanotech Inc. ever had a stock split?

No, there has never been a stock split.

Sona Nanotech Inc. Profile

Professional Services Industry
Industrials Sector
Mr. David Andrew Regan CEO
CNSX Exchange
- ISIN
Canada Country
- Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Sona Nanotech Inc. is a pioneering nanotechnology life sciences firm established in 2013 and headquartering in Halifax, Canada. The company is at the forefront of developing innovative therapeutic and diagnostic solutions primarily in the cancer treatment sector and in other critical healthcare diagnostics. Utilizing nanotechnology, Sona Nanotech Inc. focuses on creating highly specific treatments and rapid diagnostic tools, aiming to improve patient outcomes and provide faster, more accurate health insights.

Products and Services

  • Targeted Hyperthermia Therapy for Cancer Treatment

    A novel approach by Sona Nanotech which uses heat generated from nanoparticles to treat cancer by targeting only cancerous cells, leaving the healthy cells unharmed. This therapy is being developed to provide a less invasive option than traditional treatments, with the hope of reducing side effects and improving recovery times.

  • Nanomedical Therapy for the Treatment of Colorectal Cancer

    This innovative treatment method focuses on colorectal cancer by using nanotechnology to deliver medicines more effectively to the cancer cells. Sona Nanotech’s strategy enhances the drug's impact on the targeted cancer cells while minimizing the distribution of the drug to non-cancerous cells, potentially lessening the side effects commonly associated with cancer treatments.

  • Gold Nanoparticle Products

    Specializing in the production of gold nanoparticles, Sona Nanotech Inc. leverages these particles' unique properties for various applications, including medical imaging and as carriers for drug delivery. The gold nanoparticles can be used to improve the precision and effectiveness of diagnostic and therapeutic practices.

  • Lateral Flow Assay Rapid Tests

    The company designs rapid diagnostic tests based on the lateral flow assay technology. These tests offer quick, reliable results for various applications, including but not limited to, infectious disease detection, environmental testing, and food safety. The portability and ease of use make these tests an essential tool for rapid decision-making in healthcare and beyond.

  • Bovine TB Tests

    Addressing the critical need for early detection of tuberculosis in cattle, Sona Nanotech has developed a specific diagnostic test for Bovine TB. Early detection is crucial to prevent the spread of the disease, ensuring the health of cattle and reducing the potential risk to humans.

  • Concussion Screening Tests

    Expanding their reach beyond infectious diseases and cancer, Sona Nanotech is also developing rapid screening tests for concussions. These tests are designed to be administered immediately after an injury occurs, providing quick information about the potential severity of a concussion and aiding in the decision-making process for further medical care.

Contact Information

Address: Purdy’s Wharf Tower II
Phone: 902 442 0653